title: [Role of rosuvastatin in current lipid-lowering therapy].
abstract: Statins are the most widely used lipid-lowering therapy. Among them, the rosuvastatin can be well tolerated and effectively helps to reach LDL-cholesterol goals in primary and secondary cardiovascular prevention. In addition, rosuvastatin reduces triglyceride and high-sensitivity C-reactive protein level and increases high-density lipoprotein (HDL) cholesterol, too. Imaging studies demonstrated that rosuvastatin therapy can not only reduce atherosclerosis progression but might induce its regression too.
authors: Allami Egészségügyi Központ, Szakrendelo Intézet, Budapest. drabelt@t-online.hu
authors: Tatjána
authors: T
authors: Abel
authors: János
authors: J
authors: Fehér
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D018450:Disease Progression; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein; D002784:Cholesterol